Welcome to our dedicated page for National Health Investors SEC filings (Ticker: NHI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
National Health Investors, Inc. (NHI) filings document the disclosures of a self-managed healthcare and senior housing REIT. Its regulatory record includes Form 8-K reports for investor presentations, supplemental financial information, material events, executive-transition governance matters and equity distribution agreements, along with registration materials tied to common stock offerings.
Proxy materials cover board matters, executive compensation and shareholder voting topics. NHI filings also describe its Real Estate Investments and SHOP segments, capital structure, NYSE-listed common stock, lease and interest-income exposures, development and construction risks, tenant, manager and borrower performance, environmental matters and other risk factors affecting senior housing and medical facility investments.
Spaid John L reported acquisition or exercise transactions in this Form 4 filing.
National Health Investors Inc. reported that CFO and EVP Finance John L. Spaid received a corrected equity award of 5,072 shares of Common Stock on March 3, 2026, recorded at $0.00 per share as a compensation grant. An earlier report understated this award by 346 shares, and this amended Form 4 updates the figure. Following the grant, Spaid directly owns 56,600.637 shares of National Health Investors common stock.
National Health Investors Inc Schedule 13G/A amendment shows The Vanguard Group reports zero beneficial ownership of the company's common stock following an internal realignment. The filing states Vanguard and certain subsidiaries will report holdings separately and that Vanguard no longer is deemed to beneficially own securities held by those subsidiaries.
National Health Investors, Inc. established a new equity distribution program allowing it to sell up to $500,000,000 of common stock from time to time. Sales may be made through multiple banks acting as sales agents, principals, and forward sellers under a Form S-3 shelf registration.
The company can also enter into forward sale agreements under which banks borrow and sell shares now, with National Health Investors delivering shares or cash at later settlement dates. The company does not receive cash from forward sellers’ initial sales, but expects to receive proceeds when it physically settles forward contracts.
Net proceeds from direct sales and any forward settlements are expected to be used for general corporate purposes, including potential future acquisitions and repayment of indebtedness such as borrowings under its credit facilities. Sales agents and forward sellers may receive commissions of up to 1.50% of the gross sales price of shares sold through them.
National Health Investors, Inc. is offering up to $500,000,000 of its common stock through an equity distribution agreement (an at-the-market program) with multiple broker-dealers.
The shares may be sold from time to time at prevailing market prices through the Sales Agents or through Forward Sellers under forward sale agreements; we may physically, cash or net share settle forward sales. Shares outstanding were 48,459,206 as of March 12, 2026.
Donohue Lilly reported acquisition or exercise transactions in this Form 4 filing.
National Health Investors director Lilly Donohue reported receiving a grant of 1,268 shares of common stock as restricted stock.
The award was granted on March 3, 2026 and will vest in full on March 3, 2027, as long as she continues serving as a director through that date. Following this grant, her directly owned stake is 1,268 shares.
COLDEN TRACY M J reported acquisition or exercise transactions in this Form 4 filing.
National Health Investors director receives stock grant. Director Tracy M. J. Colden was awarded 1,268 shares of National Health Investors common stock on March 3, 2026 as restricted stock. These shares vest in full on March 3, 2027, subject to continued board service, bringing her direct holdings to 12,858 shares.
Todd Candice W reported acquisition or exercise transactions in this Form 4 filing.
National Health Investors Inc. director Candice W. Todd received a grant of 1,268 shares of common stock on March 3, 2026. This restricted stock award vests in full on March 3, 2027, if she continues serving as a director through that date, bringing her direct holdings to 2,563 shares.
National Health Investors director Robert Chapin reported an equity award of common stock. He acquired 1,268 shares of restricted stock on March 3, 2026 at no purchase price as a grant for board service. The award vests in full on March 3, 2027, provided he continues serving as a director through that date.
Jobe James R reported acquisition or exercise transactions in this Form 4 filing.
National Health Investors director James R. Jobe received a grant of 1,268 shares of common stock on March 3, 2026 at no cost, increasing his directly held shares to 1,268.
The restricted stock vests in full on March 3, 2027, contingent on his continued board service. Additional holdings include 33,497 common shares jointly held with his spouse and 500 common shares in an IRA SEP as of that date.
National Health Investors director receives stock grant
NATIONAL HEALTH INVESTORS INC reported that director Robert A. McCabe Jr. acquired 1,268 shares of common stock as a restricted stock award on March 3, 2026. The grant was made at no cash cost and increases his direct holdings to 43,268.96 shares.
The restricted stock vests in full on March 3, 2027, provided he continues serving as a director through that date. Until vesting, these shares typically remain subject to forfeiture conditions tied to his board service.